10.1 Controlled Substance Scheduling: Federal Framework & Alabama State Variations

10.1 Controlled Substance Scheduling: Federal Framework & Alabama State Variations

[!NOTE] Dual Sovereignty & the Preemption Principle: The regulation of controlled substances in the United States operates under a dual-sovereignty framework governed simultaneously by the federal Comprehensive Drug Abuse Prevention and Control Act of 1970 (Title II, 21 U.S.C. § 801 et seq.) and state statutes. Under the constitutional doctrine of federal preemption and the federal Controlled Substances Act (21 U.S.C. § 903), states may enact controlled substance regulations that are stricter than federal law, but they may never be more lenient. When federal and state laws conflict, the pharmacist must always adhere to the more stringent requirement. For the Alabama MPJE, candidates must master both the standard federal schedules and Alabama's unique statutory additions and rescheduling actions.

Controlled substances are pharmaceutical agents and chemicals subject to strict government oversight because of their recognized potential for abuse, addiction, diversion, and physiological harm. While federal law establishes a uniform baseline across the nation, the State of Alabama exercises its inherent police powers through the Alabama Uniform Controlled Substances Act to regulate certain substances with greater rigor than the federal government.

---

The Federal Controlled Substances Act Framework (21 U.S.C. § 812)

The federal Controlled Substances Act (CSA) organizes medications, chemicals, and illicit compounds into five distinct schedules based on three core statutory criteria:

1. Potential for Abuse: The drug's likelihood of being misused, diverted, or taken in quantities that create hazards to health and safety.
2. Accepted Medical Use: Whether the substance has an established, recognized therapeutic utility in medical treatment in the United States (typically confirmed by FDA new drug approval).
3. Dependence Liability: The physical dependence (withdrawal syndrome upon cessation) and psychological dependence (compulsive drug-seeking behavior) produced by chronic administration.

+------------------------------------------------------------------------------------------------------------------+
|                                 Federal CSA Five-Schedule Classification System                                  |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+
| Schedule | Abuse Potential      | Accepted Medical Use? | Dependence Liability        | Classical Examples       |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+
| C-I      | High                 | None in the U.S.      | Severe lack of safety       | Heroin, LSD, MDMA,       |
|          |                      |                       |                             | Peyote, Methaqualone     |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+
| C-II     | High                 | Yes                   | Severe physical and/or      | Morphine, Oxycodone,     |
|          |                      |                       | severe psychological        | Fentanyl, Methadone,     |
|          |                      |                       |                             | Amphetamine, Cocaine     |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+
| C-III    | Less than C-I/C-II   | Yes                   | Moderate/low physical;      | Buprenorphine, Ketamine, |
|          |                      |                       | high psychological          | Anabolic Steroids, T#3   |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+
| C-IV     | Less than C-III      | Yes                   | Limited physical or         | Benzodiazepines, Soma,   |
|          |                      |                       | psychological               | Zolpidem, Tramadol       |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+
| C-V      | Less than C-IV       | Yes                   | Limited physical or         | Codeine cough syrups     |
|          |                      |                       | psychological relative to IV| (<=200mg/100mL), Lyrica  |
+----------+----------------------+-----------------------+-----------------------------+--------------------------+

Clinical and Regulatory Schedule Boundaries

• Schedule I (C-I): Possesses high abuse potential and no currently accepted medical use in treatment in the United States. These agents cannot be prescribed, administered, or dispensed in routine pharmacy practice. They may be procured only by researchers registered with the DEA under an approved Investigational New Drug (IND) research protocol.
• Schedule II (C-II): High abuse potential with accepted medical use, but abuse may lead to severe psychological or physical dependence. Under federal and Alabama law, verbal (oral) orders are prohibited except in immediate emergency situations; prescriptions cannot carry refills; and physical storage requires either a securely locked, substantially constructed cabinet or compliant dispersal among non-controlled inventory.
• Schedule III (C-III): Potential for abuse is less than substances in Schedules I and II. Abuse may lead to moderate or low physical dependence or high psychological dependence. Prescriptions may be refilled up to five (5) times within six (6) months from the date of issuance.
• Schedule IV (C-IV): Low potential for abuse relative to Schedule III. Abuse may lead to limited physical dependence or psychological dependence. Refill limits mirror Schedule III (maximum five refills within six months).
• Schedule V (C-V): Low potential for abuse relative to Schedule IV. Consists primarily of preparations containing limited quantities of certain narcotics for antitussive, antidiarrheal, or analgesic purposes (e.g., codeine cough preparations containing not more than 200 mg of codeine per 100 mL or 100 g), as well as anticonvulsants like pregabalin (Lyrica) and lacosamide (Vimpat).

---

Alabama Uniform Controlled Substances Act (Ala. Code Title 20 Chapter 2)

In Alabama, state-level controlled substance regulation is codified in the Alabama Uniform Controlled Substances Act (Code of Alabama 1975 § 20-2-1 through § 20-2-190).

The State Board of Health Scheduling Authority

A critical legal distinction frequently examined on the Alabama MPJE centers on which state agency holds statutory authority to schedule controlled substances.

[!IMPORTANT] Statutory Scheduling Authority: Under Code of Alabama 1975 § 20-2-20, the Alabama State Board of Health (operating through the State Health Officer and the Alabama Department of Public Health - ADPH)—NOT the Alabama State Board of Pharmacy (ALBOP)—is vested with statutory authority to add, delete, or reschedule substances on the Alabama controlled substance schedules.

When evaluating whether to add, delete, or reschedule a substance, the State Board of Health must consider eight statutory criteria:

1. The actual or relative potential for abuse;
2. The scientific evidence of its pharmacological effect, if known;
3. The state of current scientific knowledge regarding the substance;
4. The history and current pattern of abuse;
5. The scope, duration, and significance of abuse;
6. The risk to the public health;
7. The potential of the substance to produce psychic or physiological dependence liability; and
8. Whether the substance is an immediate precursor of a substance already controlled under the article.

Harmonization with Federal Scheduling Actions

Under Ala. Code § 20-2-20(d), if any substance is designated, rescheduled, or deleted as a controlled substance under federal law and notice thereof is given to the State Board of Health, the State Board of Health shall similarly control the substance after thirty (30) days from publication in the Federal Register. However, if the State Board of Health objects to the federal inclusion, it must publish its reasons for objection and afford all interested parties an opportunity to be heard. This automatic adoption mechanism ensures that federal scheduling updates flow seamlessly into Alabama law unless the State Board of Health explicitly issues an administrative objection.

---

Critical Alabama State Scheduling Variations

Alabama pharmacy jurisprudence features several vital state-level variations where Alabama law is strictly more stringent than the federal CSA. Candidates must memorize these state-specific classifications.

+------------------------------------------------------------------------------------------------------------------+
|                                 Alabama State Scheduling Variations Matrix                                       |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Drug / Chemical Entity     | Federal Schedule      | Alabama Schedule     | Practice Implications in Alabama     |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Gabapentin (Neurontin)     | Non-Controlled        | Schedule V (C-V)     | Requires DEA; Max 5 refills in 6 mo; |
|                            | (Legend only)         | (Eff. Nov 18, 2019)  | Daily PDMP reporting; Jan 15 count   |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Butalbital / APAP /        | Exempt from CSA       | Schedule III (C-III) | Requires DEA; Max 5 refills in 6 mo; |
| Caffeine (Fioricet)        | (21 C.F.R. § 1308.32) | (No exemption in AL) | C-III recordkeeping and storage      |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Butalbital / Aspirin /     | Schedule III (C-III)  | Schedule III (C-III) | Requires DEA; Max 5 refills in 6 mo; |
| Caffeine (Fiorinal)        |                       |                      | Standard C-III requirements          |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Carisoprodol (Soma)        | Schedule IV (C-IV)    | Schedule IV (C-IV)   | Controlled both federally and AL;    |
|                            |                       |                      | Active metabolite is meprobamate     |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Anabolic Steroids          | Schedule III (C-III)  | Schedule III (C-III) | Explicit prohibition against use for |
| (Testosterone, etc.)       |                       | (Ala. Code § 20-2-26)| athletic or bodybuilding enhancement |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| Industrial Hemp CBD        | Non-Controlled        | Non-Controlled       | Commercial OTC sales allowed if      |
| (<= 0.3% delta-9 THC)      | (2018 Farm Bill)      |                      | delta-9 THC <= 0.3% dry weight basis |
+----------------------------+-----------------------+----------------------+--------------------------------------+
| State Medical Cannabis     | Schedule I (C-I)      | State-Regulated      | Dispensed ONLY by AMCC dispensaries; |
| (SB 46 / AMCC Program)     | (Federal law)         | Medical Program      | Retail pharmacies CANNOT dispense    |
+----------------------------+-----------------------+----------------------+--------------------------------------+

1. Gabapentin (Neurontin, Gralise, Horizant) — Alabama Schedule V

In response to mounting epidemiological data demonstrating that gabapentin was being widely diverted, misused, and co-ingested with illicit opioids to potentiate euphoric respiratory depressant effects, the Alabama State Board of Health promulgated an administrative order classifying gabapentin as a Schedule V controlled substance effective November 18, 2019.

Although gabapentin remains an unscheduled legend drug under federal law, in Alabama it carries all legal mandates of a Schedule V drug:

• Prescriber Authority: The prescriber must possess an active federal DEA registration and an active Alabama Controlled Substances Certificate (ACSC).
• Refill Restrictions: Refills are strictly limited to a maximum of five (5) refills within six (6) months from the date the prescription is written. A prescription written for "PRN refills" or 11 refills cannot be honored beyond five refills or six months.
• PDMP Reporting: Every dispensing of gabapentin must be reported electronically to the Alabama Prescription Drug Monitoring Program (PDMP) by the close of the next business day.
• Storage & Security: Must be stored in accordance with controlled substance security protocols (dispersed among stock or locked in a safe).
• Annual Inventory: Must be counted and documented during the mandatory annual controlled substance inventory on January 15.

2. Butalbital Combination Products — Alabama Schedule III

A long-standing point of confusion for multi-state practitioners involves butalbital-containing analgesics. Under federal regulations (21 C.F.R. § 1308.32), the DEA established a list of "exempted prescription products" where combinations containing certain depressants or barbiturates combined with non-controlled active ingredients in specific ratios were exempted from federal scheduling. Under this federal exemption, Fioricet (butalbital 50 mg / acetaminophen 325 mg / caffeine 40 mg) is non-controlled federally, whereas Fiorinal (butalbital 50 mg / aspirin 325 mg / caffeine 40 mg) remained a federal Schedule III substance.

[!CRITICAL] The Fioricet Rule in Alabama: The State of Alabama does not recognize the federal scheduling exemption for butalbital combinations. Under Code of Alabama 1975 and Board rules, ALL butalbital-containing combination products—including Fioricet—are classified as Schedule III controlled substances in Alabama. A prescription for Fioricet written by an out-of-state prescriber cannot be filled in Alabama unless the prescriber holds a valid DEA registration, and the prescription is filed, refilled, and recorded strictly as a Schedule III controlled substance.

3. Carisoprodol (Soma) — Schedule IV

Carisoprodol is a centrally acting skeletal muscle relaxant whose primary active metabolite is meprobamate (a Schedule IV anxiolytic). In 2012, the DEA placed carisoprodol into Schedule IV nationwide. Alabama law mirrors federal law: carisoprodol is regulated as a Schedule IV controlled substance, restricted to five refills within six months, and monitored through the state PDMP.

4. Anabolic Steroids — Schedule III

Under federal law and Code of Alabama 1975 § 20-2-26, all anabolic steroids (including testosterone, nandrolone, stanozolol, and oxandrolone) are classified as Schedule III controlled substances. Alabama law contains explicit statutory language prohibiting practitioners from prescribing, administering, or dispensing anabolic steroids for the purpose of enhancing athletic performance, increasing muscle mass, or bodybuilding. Dispensing anabolic steroids for non-therapeutic bodybuilding purposes constitutes unlawful prescribing under Alabama law.

---

Cannabidiol (CBD) and the Alabama Medical Cannabis Framework

Jurisprudence surrounding cannabis and hemp products requires distinguishing between federal definitions, historical state pilot programs, and the current comprehensive Alabama medical cannabis structure.

Industrial Hemp vs. Controlled Marijuana

Under the federal Agriculture Improvement Act of 2018 (2018 Farm Bill) and corresponding Alabama legislation, industrial hemp is defined as the plant Cannabis sativa L. and any part of that plant with a delta-9-tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis. Hemp and hemp-derived cannabidiol (CBD) products meeting this 0.3% threshold are legal commodities that may be sold over-the-counter without a prescription in grocery stores, pharmacies, and specialty retailers. If a CBD product exceeds 0.3% delta-9 THC, it falls legally into the definition of marijuana (Schedule I under federal CSA).

Legislative Evolution: Carly's Law and Leni's Law

• Carly's Law (2014, Ala. Code § 13A-12-214.2): Authorized the University of Alabama at Birmingham (UAB) Department of Neurology to conduct an FDA-authorized clinical research study on the use of high-CBD, low-THC cannabis oil for individuals with severe, debilitating pediatric epileptic conditions.
• Leni's Law (2016, Ala. Code § 13A-12-214.3): Expanded statutory protections by providing an affirmative legal defense against state criminal prosecution for individuals possessing CBD oil containing up to 3% THC for the treatment of intractable epilepsy or other severe, debilitating medical conditions.

The Alabama Medical Cannabis Act (SB 46 / Act 2021-450)

In 2021, the Alabama Legislature enacted the Alabama Medical Cannabis Act (Code of Alabama 1975 § 20-2A-1 et seq.), creating a strictly regulated medical cannabis program administered by the Alabama Medical Cannabis Commission (AMCC).

Key structural elements of the Alabama Medical Cannabis Act include:

1. Qualifying Conditions: Certification is restricted to patients diagnosed with specific statutory medical conditions, including autism spectrum disorder, cancer-related pain/nausea, chronic pain, Crohn's disease, epilepsy, HIV/AIDS-related nausea, depression, panic disorder, PTSD, terminal illnesses, and persistent nausea/vomiting.
2. Prescriber Certification: Physicians must undergo specialized training, receive certification from the Alabama State Board of Medical Examiners, and register with the AMCC. Physicians do not write a standard prescription; instead, they enter a medical recommendation into the centralized AMCC patient registry.
3. Patient Registry Card: Qualified patients obtain an AMCC-issued medical cannabis identification card.
4. Permitted Dosage Forms: Alabama law permits medical cannabis only in non-smokable, non-vapeable formulations. Authorized formulations include: tablets, capsules, tinctures, liquid oral suspensions, topical creams/gels, transdermal patches, and suppositories.
5. Statutory Prohibitions: Raw plant material (flower/bud), smokable cannabis products, vape cartridges, and food items (such as baked goods, candies, and gummies) are strictly illegal under Alabama law.

[!WARNING] Retail Pharmacy Prohibition: A core MPJE test concept is that licensed retail community and hospital pharmacies in Alabama DO NOT stock or dispense medical cannabis. Medical cannabis may only be distributed by dedicated, state-licensed medical cannabis dispensaries authorized directly by the AMCC. A pharmacist in a traditional pharmacy who receives a physician's recommendation for medical cannabis cannot dispense the medication and must direct the patient to an AMCC dispensary.